AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16829486 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative task with manipulations (recency of narrative presentation, narrative repetition, type of false-memory item, testing delay, repeated testing)
Number of subjects: 0
Study 16829486 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated testing manipulation
Number of subjects: 0
Study 14739739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-control strategy
Number of subjects: 0
Study 14739739 — intervention group
Group type: COMPARATOR
Intervention: Rate-control strategy
Number of subjects: 0
Study 11335733 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (40 mg/kg/d in 3 daily doses)
Number of subjects: 188
Study 11335733 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (amoxicillin 45 mg/kg/d in 2 daily doses)
Number of subjects: 188
Study 11335733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 9358333 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive survival trials with skewed randomization based on logrank statistic
Number of subjects: 0
Study 9358333 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual test statistic under proposed allocation scheme
Number of subjects: 0
Study 7871042 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 600 mg/70 kg
Number of subjects: 50
Study 7871042 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg caffeine)
Number of subjects: 50
Study 7871042 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (all doses)
Number of subjects: 50
Study 2876879 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (20 mg i.m. on the first day and 20 mg p.o. daily from day 2 to 21)
Number of subjects: 53
Study 2876879 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipothiazine palmitate (100 mg i.m. on the first day and daily glass of milk with grenadine from day 2 to 21)
Number of subjects: 53
Study 31198076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management training (CBSM)
Number of subjects: 43
Study 31198076 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WCG)
Number of subjects: 43
Study 29798296 — intervention group
Group type: EXPERIMENTAL
Intervention: Weisu granules combined with Lanqin oral solution
Number of subjects: 180
Study 29798296 — intervention group
Group type: COMPARATOR
Intervention: Lanqin oral solution
Number of subjects: 180
Study 29798296 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole Magnesium Enteric-coated Tablets and Lanqin oral solution
Number of subjects: 180
Study 26552755 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 2513
Study 26552755 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 2513
Study 26552755 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2513
Study 25498565 — intervention group
Group type: EXPERIMENTAL
Intervention: More rigorous dose calculation algorithm (DCA)
Number of subjects: 754
Study 25498565 — intervention group
Group type: COMPARATOR
Intervention: Laxative as a method of bowel preparation
Number of subjects: 754
Study 21386036 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 78
Study 21386036 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 mg/5 mg and Ezetimibe
Number of subjects: 78
Study 20423469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic counselling (by regular home visits and telephone calls) and oral nutritional supplementation for three months after surgery
Number of subjects: 0
Study 20423469 — intervention group
Group type: COMPARATOR
Intervention: Usual dietetic care as provided by the hospital
Number of subjects: 0
Study 18535196 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 635
Study 18535196 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 635
Study 15744633 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol withdrawal patients
Number of subjects: 40
Study 15744633 — intervention group
Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 40
Study 12587819 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose i.v. cyclophosphamide (200‐400 mg per month) and prednisone (mean dose 20.5 mg per day)
Number of subjects: 60
Study 12587819 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (mean dose 20.5 mg per day) only or with antimalarials
Number of subjects: 60
Study 11099587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) dexamethasone (0.6 mg/kg, maximum 8 mg)
Number of subjects: 277
Study 11099587 — intervention group
Group type: COMPARATOR
Intervention: Oral (PO) dexamethasone (0.6 mg/kg, maximum 8 mg)
Number of subjects: 277
Study 9074572 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily)
Number of subjects: 722
Study 9074572 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50 mg three times daily)
Number of subjects: 722
Study 9074572 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 722
Study 8339536 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 318
Study 8339536 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 318
Study 8339536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 8339536 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 318
Study 3532694 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. diazoxide (75-150 mg bolus injections)
Number of subjects: 64
Study 3532694 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. dihydralazine (6-12.5 mg bolus injections)
Number of subjects: 64
Study 3532694 — intervention group
Group type: COMPARATOR
Intervention: Initial treatment with furosemide i.v.
Number of subjects: 64
Study 28637143 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor during grocery shelving
Number of subjects: 32
Study 28637143 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor during floor sweeping
Number of subjects: 32
Study 28637143 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor during crank ergometer
Number of subjects: 32
Study 28637143 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor during table dusting
Number of subjects: 32
Study 28637143 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor during typing
Number of subjects: 32
Study 28637143 — intervention group
Group type: COMPARATOR
Intervention: Hypothesis testing of group equivalence
Number of subjects: 32
Study 27236074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 60
Study 24735420 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help with individual support by a psychologist
Number of subjects: 150
Study 24735420 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help with therapist-guided group support
Number of subjects: 150
Study 24735420 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 150
Study 24413436 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid restriction (FR) - 10% of control intake
Number of subjects: 12
Study 24413436 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) - 25% of control intake
Number of subjects: 12
Study 24413436 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid and energy restriction (F+ER) - 25% of control energy and 10% of control water intake
Number of subjects: 12
Study 24413436 — intervention group
Group type: COMPARATOR
Intervention: Control (C) - Adequate energy and water intake
Number of subjects: 12
Study 21227004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 108
Study 21227004 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 108
Study 19008006 — intervention group
Group type: EXPERIMENTAL
Intervention: One-leg cycling aerobic training program (21 min, alternating 3 min at 70% and 3 min at 85% of VO(2 peak), 15 sessions over 5 weeks)
Number of subjects: 24
Study 19008006 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (5 weeks without cardiorespiratory training)
Number of subjects: 24
Study 16378639 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided Zyoptix Ablation Refinement software (ZAR) LASIK
Number of subjects: 20
Study 16378639 — intervention group
Group type: COMPARATOR
Intervention: Standard Planoscan LASIK
Number of subjects: 20
Study 14694208 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA)
Number of subjects: 19
Study 14694208 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA)
Number of subjects: 19
Study 14694208 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids (TRANS)
Number of subjects: 19
Study 14694208 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 19
Study 11314240 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol 50 micrograms/g/ml solution
Number of subjects: 42
Study 11314240 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate 1% lotion
Number of subjects: 42
Study 9007116 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with cisplatin
Number of subjects: 0
Study 9007116 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with carboplatin
Number of subjects: 0
Study 9007116 — intervention group
Group type: COMPARATOR
Intervention: Single-agent paclitaxel
Number of subjects: 0
Study 9007116 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour infusion of paclitaxel
Number of subjects: 0
Study 9007116 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour infusion of paclitaxel
Number of subjects: 0
Study 9007116 — intervention group
Group type: COMPARATOR
Intervention: Etoposide/cisplatin regimen
Number of subjects: 0
Study 30262136 — intervention group
Group type: EXPERIMENTAL
Intervention: BEVZ92
Number of subjects: 142
Study 30262136 — intervention group
Group type: COMPARATOR
Intervention: Reference bevacizumab
Number of subjects: 142
Study 26953895 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 343
Study 24684662 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-help psychoeducation programme
Number of subjects: 128
Study 24684662 — intervention group
Group type: COMPARATOR
Intervention: Control group (no participation in the programme)
Number of subjects: 128
Study 23436922 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 53
Study 23436922 — intervention group
Group type: COMPARATOR
Intervention: AZT/3TC
Number of subjects: 53
Study 20595411 — intervention group
Group type: EXPERIMENTAL
Intervention: STAIR/Exposure
Number of subjects: 104
Study 20595411 — intervention group
Group type: COMPARATOR
Intervention: Support/Exposure
Number of subjects: 104
Study 20595411 — intervention group
Group type: COMPARATOR
Intervention: STAIR/Support
Number of subjects: 104
Study 18042657 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus of attention during motor skill practice
Number of subjects: 66
Study 18042657 — intervention group
Group type: COMPARATOR
Intervention: Internal focus of attention during motor skill practice
Number of subjects: 66
Study 16381626 — intervention group
Group type: EXPERIMENTAL
Intervention: Every-3-week therapy (200 mg/m2 paclitaxel, AUC 6 mg/mL/min carboplatin, trastuzumab initial 8 mg/kg, subsequent 6 mg/kg every 21 days for 8 cycles)
Number of subjects: 91
Study 16381626 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly therapy (80 mg/m2 paclitaxel, AUC 2 mg/mL/min carboplatin, trastuzumab initial 4 mg/kg, subsequent 2 mg/kg every 4 weeks for 6 cycles)
Number of subjects: 91
Study 16381626 — intervention group
Group type: COMPARATOR
Intervention: Weekly therapy
Number of subjects: 91
Study 16381626 — intervention group
Group type: COMPARATOR
Intervention: Every-3-week therapy
Number of subjects: 91
Study 12108800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 12
Study 12108800 — intervention group
Group type: COMPARATOR
Intervention: Attention-Support Control (AS-Control)
Number of subjects: 12
Study 12108800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CBT and AS-Control)
Number of subjects: 12
Study 10428124 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg every 12 hours)
Number of subjects: 3011
Study 10428124 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (adjusted-dose)
Number of subjects: 3011
Study 7555502 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise (walking at least 10,000 steps/day, monitored by pedometer)
Number of subjects: 24
Study 7555502 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (normal daily routine, 4,500 +/- 290 steps/day)
Number of subjects: 24
Study 2372083 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic knee brace
Number of subjects: 1396
Study 2372083 — intervention group
Group type: COMPARATOR
Intervention: Control (no knee brace)
Number of subjects: 1396
Study 6158861 — intervention group
Group type: EXPERIMENTAL
Intervention: dextran 40 (Rheomacrodex)
Number of subjects: 32
Study 6158861 — intervention group
Group type: EXPERIMENTAL
Intervention: plasmanate
Number of subjects: 32
Study 6158861 — intervention group
Group type: COMPARATOR
Intervention: Control (routine treatment with sedatives, bed rest, and magnesium sulfate)
Number of subjects: 32
Study 31072214 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 33
Study 31072214 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 33
Study 27593801 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigation-assisted aspiration and electro-acupuncture (NAEA)
Number of subjects: 240
Study 27593801 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigation-assisted aspiration (NA)
Number of subjects: 240
Study 27593801 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 240
Study 27593801 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (Control)
Number of subjects: 240
Study 26465152 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI withdrawal after six months
Number of subjects: 180
Study 26465152 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus/sirolimus
Number of subjects: 180
Study 26465152 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil/sirolimus
Number of subjects: 180
Study 24266796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 24
Study 24266796 — intervention group
Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 24
Study 21864907 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) formulation, 600 mg single dose
Number of subjects: 48
Study 21864907 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation, 300 mg single dose
Number of subjects: 48
Study 21864907 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) formulation, 600 mg q12h multiple doses
Number of subjects: 48
Study 21864907 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation, 300 mg q6h multiple doses
Number of subjects: 48
Study 19702486 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 1.8 mg/kg per day
Number of subjects: 245
Study 19702486 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5 mg/kg per day, 1.2 mg/kg per day, 1.8 mg/kg per day)
Number of subjects: 245
Study 19702486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 16900287 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Revascularisation Outcome Questionnaire (CROQ)
Number of subjects: 199
Study 16900287 — intervention group
Group type: COMPARATOR
Intervention: Seattle Angina Questionnaire (SAQ)
Number of subjects: 199
Study 16900287 — intervention group
Group type: COMPARATOR
Intervention: SF‐36
Number of subjects: 199
Study 15627870 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (9 microg) twice a day
Number of subjects: 40
Study 15627870 — intervention group
Group type: COMPARATOR
Intervention: Oral montelukast (10 microg) once a day
Number of subjects: 40
Study 11840750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic foldable lens implantation
Number of subjects: 190
Study 11840750 — intervention group
Group type: COMPARATOR
Intervention: PMMA intraocular lens (IOL) implantation
Number of subjects: 190
Study 9412655 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide 100 mg/m2, Methotrexate 40 mg/m2, 5-Fluorouracil 600 mg/m2 (CMF)
Number of subjects: 107
Study 9412655 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin 75 mg/m2 and Vincristine 0.75 mg/m2 (EV)
Number of subjects: 107
Study 9412655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C 10 mg/m2 and Vindesine 2 mg/m2 (MVs)
Number of subjects: 107
Study 8276739 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine at top doses of 150 mg/day for 3 weeks
Number of subjects: 18
Study 8276739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3690230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) induced hypotensive anaesthesia
Number of subjects: 18
Study 3690230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SNP)
Number of subjects: 18
Study 30312327 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 72
Study 30312327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 28780551 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous Counselling And Nicotine (ICAN) QUIT in Pregnancy intervention including webinar training, educational resources, free oral nicotine replacement therapy (NRT), and audit and feedback.
Number of subjects: 6
Study 28780551 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 6
Study 26121878 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 µg Qd
Number of subjects: 220
Study 26121878 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium 40 µg Qid
Number of subjects: 220
Study 23926588 — intervention group
Group type: EXPERIMENTAL
Intervention: Way Milano implants
Number of subjects: 64
Study 23926588 — intervention group
Group type: COMPARATOR
Intervention: Kentron implants
Number of subjects: 64
Study 21397868 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 30
Study 21397868 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (PCT)
Number of subjects: 30
Study 18358928 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with FOLFOX4 (6 cycles before and 6 cycles after surgery)
Number of subjects: 364
Study 18358928 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 364
Study 18358928 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with FOLFOX4
Number of subjects: 364
Study 15737450 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi‐continuous lengthening (1440 steps per day)
Number of subjects: 20
Study 15737450 — intervention group
Group type: EXPERIMENTAL
Intervention: Step lengthening (twice a day)
Number of subjects: 20
Study 12534148 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR inhibitory agents
Number of subjects: 0
Study 10358689 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer risk counseling intervention
Number of subjects: 508
Study 10358689 — intervention group
Group type: COMPARATOR
Intervention: General health education control intervention
Number of subjects: 508
Study 7863991 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator (ICD)
Number of subjects: 1200
Study 7863991 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (amiodarone and sotalol)
Number of subjects: 1200
Study 1778484 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion programs participation
Number of subjects: 0
Study 6120346 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Sodium (Ciba)
Number of subjects: 19
Study 6120346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31957521 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 412
Study 31957521 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 412
Study 30471012 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg every 2 weeks (Q2W)
Number of subjects: 1849
Study 30471012 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab (45 mg for patients ≤ 100 kg; 90 mg for patients > 100 kg)
Number of subjects: 1849
Study 30471012 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg Q2W
Number of subjects: 1849
Study 30325777 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment interruption (ATI)
Number of subjects: 10
Study 27907921 — intervention group
Group type: EXPERIMENTAL
Intervention: DCF (docetaxel 70 mg/m2, cisplatin 70 mg/m2 on day 1, and 5‐fluorouracil 700 mg/m2 for 5 days) every 3 weeks
Number of subjects: 162
Study 27907921 — intervention group
Group type: COMPARATOR
Intervention: ACF (adriamycin 35 mg/m2, cisplatin 70 mg/m2 on day 1, and 5‐FU 700 mg/m2 for 7 days) every 4 weeks
Number of subjects: 162
Study 26219281 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored lifestyle intervention
Number of subjects: 340
Study 26219281 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 340
Study 23114369 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 vaccine (20 µg, 60 µg, 200 µg)
Number of subjects: 127
Study 23114369 — intervention group
Group type: COMPARATOR
Intervention: Twinrix (active control)
Number of subjects: 127
Study 21861128 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 400 mg orally daily
Number of subjects: 0
Study 21861128 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan 350 mg/m2 intravenously every 3 weeks
Number of subjects: 0
Study 18752983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical lateral glide mobilizations
Number of subjects: 21